-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 Ot7Tonxl4KLB7SCr3zgUU3bfjeRRH34IG/Rx7/2eTcDeb/zjqcr7v9OjVRE6eeVA
 +yAmi7ahZJQnqDwj04HGkA==

<SEC-DOCUMENT>0001144204-05-028874.txt : 20050915
<SEC-HEADER>0001144204-05-028874.hdr.sgml : 20050915
<ACCEPTANCE-DATETIME>20050915060310
ACCESSION NUMBER:		0001144204-05-028874
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20050915
FILED AS OF DATE:		20050915
DATE AS OF CHANGE:		20050915

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			pSivida LTD
		CENTRAL INDEX KEY:			0001314102
		STANDARD INDUSTRIAL CLASSIFICATION:	LABORATORY ANALYTICAL INSTRUMENTS [3826]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51122
		FILM NUMBER:		051085580

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12 BGC CENTRE
		STREET 2:		28 THE ESPLANADE
		CITY:			PERTH
		STATE:			C3
		ZIP:			6000
		BUSINESS PHONE:		61 8 9226 5099

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12 BGC CENTRE
		STREET 2:		28 THE ESPLANADE
		CITY:			PERTH
		STATE:			C3
		ZIP:			6000
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>v025743_6k.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><a name="return"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>SECURITIES
        AND EXCHANGE COMMISSION</strong></font></a></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Washington,
        D.C. 20549</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>FORM
        6-K</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">REPORT
        OF
        FOREIGN ISSUER</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to Rule 13a-16 or 15d-16 of</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">the
        Securities Exchange Act of 1934</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>For
        the month of September 2005</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Commission
        File Number 000-5112</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">2</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 12pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Translation
        of registrant&#8217;s name into English) </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Level
        12
        BGC Centre</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">28
        The
        Esplanade</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Perth
        WA
        6000</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Address
        of principal executive offices)</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">(Indicate
        by check mark whether the registrant files or will file annual reports under
        cover Form&#160;20-F or Form&#160;40-F). </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 180pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Form
        20-F&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Form
        40-F <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(1):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark if the registrant is submitting the Form 6-K in paper as permitted
        by Regulation S-T Rule 101(b)(7):</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Indicate
        by check mark whether the registrant by furnishing the information contained
        in
        this Form is also thereby furnishing the information to the Commission pursuant
        to Rule&#160;12g3-2(b) under the Securities Exchange Act of 1934.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Yes&#160;<font style="DISPLAY: inline; FONT-FAMILY: Wingdings">o</font></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;No
        <font style="DISPLAY: inline; FONT-FAMILY: Wingdings">x</font></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 225pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">If
        "Yes"
        is marked, indicate below the file number assigned to the registrant in
        connection with Rule&#160;12g3-2(b): 82- ___. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>SIGNATURE
        </strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Pursuant
        to the requirements of the Securities Exchange Act of 1934, the registrant,
        pSivida Limited, has duly caused this report to be signed on its behalf by
        the
        undersigned, thereunto duly authorized. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">
        <table align="center" bgcolor="#ffffff" border="0" cellpadding="0" cellspacing="0" width="100%">

            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font size="2">Date: September 15, 2005</font>&#160;</td>
              <td width="1%">&#160;</td>
              <td width="49%">&#160;</td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td width="50%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="1%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td width="49%"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                Limited</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;<br>&#160;</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td>&#160;</td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">By:&#160;&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">/s/&#160;Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="FONT-FAMILY: Times New Roman" size="1">&#160;</font></td>
              <td align="left">
                <hr style="COLOR: #000000" align="left" noshade size="2" width="80%"><font size="2">Aaron
                Finlay</font></td>
            </tr>
            <tr valign="top" bgcolor="#ffffff">
              <td colspan="2"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font></td>
              <td><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>Chief
                Financial Officer and Company
                Secretary</em></font></td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div id="PN" style="PAGE-BREAK-AFTER: always">
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
            </div>
            <div style="WIDTH: 100%; TEXT-ALIGN: center">
              <hr style="COLOR: black" noshade size="2">
            </div>
          </div>
          <div id="HDR">
            <div id="GLHDR" style="WIDTH: 100%" align="right">
            </div>
          </div>
        </div>
        <div>&#160;</div>
        <div>&#160;</div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong><em><u>EXHIBIT
        INDEX</u></em></strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">
          <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>EXHIBIT
            99.1:</strong>&#160;&#160;&#160;&#160;&#160;&#160;<font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
            Completes Manufacturing Infrastructure for BrachySil</font><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman, serif"><sup>TM</sup></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
            Cancer
            Therapy</font></font></div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><br>
          <div>&#160;</div>
          <div>&#160;</div>
          <div>&#160;</div>&#160;&#160;</div>
      </div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center"><font style="DISPLAY: inline; FONT-SIZE: 8pt; FONT-FAMILY: Times New Roman">-2-</font></div>
        <div style="WIDTH: 100%; TEXT-ALIGN: center">
          <hr style="COLOR: black" noshade size="2">
        </div>
      </div>
      <div id="HDR">
        <div id="GLHDR" style="WIDTH: 100%" align="right">
        </div>
      </div>
    </div>
    <div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>v025743_ex99-1.htm
<TEXT>
<html>
  <head>
    <title>
      Unassociated Document
</title><!-- Licensed to: vf-->
<!-- Document Created using EDGARIZER HTML 3.0.0.39895 -->
<!-- Copyright 2005 EDGARfilings, Ltd., an IEC company.-->
<!-- All rights reserved EDGARfilings.com -->
</head>
  <body bgcolor="#ffffff">
    <div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="right"><img src="v025743_logo1.jpg" alt=""></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="right"><br>&#160;</div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="50%"><strong><font size="2">ASX/MEDIA
                RELEASE</font></strong>&#160;</td>
              <td width="50%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"><strong><font size="2">15
                  September
                  2005</font></strong></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="50%">&#160;</td>
              <td width="50%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font id="TAB2" style="COLOR: black; LETTER-SPACING: 161.1pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 0.9pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>&#160;</strong></font><font id="TAB2" style="COLOR: black; LETTER-SPACING: 27pt">&#160;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Completes Manufacturing Infrastructure for</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 18pt; FONT-FAMILY: Times New Roman"><strong>BrachySil&#8482;
        Cancer Therapy</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center">&#160;</div>
      <div align="center">
        <table bgcolor="#ffffff" cellpadding="0" cellspacing="0" width="100%">

            <tr bgcolor="#ffffff">
              <td width="100%">
                <div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"><strong><em><font size="2">BrachySil&#8482;
                  manufacturing process
                  completed at state-of-the-art Auriga Medical&#8482;
                  facility</font></em></strong></div>
              </td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="100%" style="BORDER-BOTTOM: #000000 thin solid">&#160;</td>
            </tr>
            <tr bgcolor="#ffffff">
              <td width="100%">&#160;</td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Global
        nanotechnology company pSivida Limited </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>(ASX:PSD,
        NASDAQ:PSDV, Xetra:PSI)</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">
        is
        pleased to announce that it&#8217;s manufacturing partner QSA* has completed the
        construction and validation of a state-of-the-art cleanroom facility, dedicated
        to the supply of pSivida&#8217;s lead cancer therapy BrachySil&#8482;, at QSA&#8217;s Auriga
        Medical&#8482; facility in Braunschweig, Germany.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">This
        cGMP
        facility will fulfil the final process in the manufacture of BrachySil&#8482; for
        future clinical and commercial use, and represents the crucial final stage
        in
        establishing the manufacturing and supply infrastructure to support BrachySil&#8482;
        as it advances through clinical trials towards the market.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">BrachySil&#8482;
        (32-P BioSilicon&#8482;) has shown excellent results in Phase IIa clinical trials as a
        radiotherapy for the treatment of inoperable primary liver cancer, where
        it is
        delivered directly into the tumors without surgery, a procedure known as
        brachytherapy. pSivida is currently preparing to begin Phase IIb dose-profiling
        studies with BrachySil&#8482; in this indication and expects to treat its first
        patient before the end of 2005. The Company is also planning Phase IIa trials
        with BrachySil&#8482; to evaluate its safety and efficacy in patients suffering from
        pancreatic cancer. This trial is also on schedule to begin in late
        2005.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        and QSA entered into an extendable three-year manufacturing agreement for
        BrachySil&#8482; in March 2004. Under the terms of the agreement, QSA&#8217;s specialist
        brachytherapy and radioimmunotherapy business Auriga Medical&#8482; was to design and
        construct a dedicated facility, optimized for the processing of BrachySil&#8482; (32-P
        BioSilicon&#8482;). Auriga Medical&#8482; will also manage the supply logistics for clinical
        and commercial use.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida&#8217;s
        Managing Director, Gavin Rezos, said, &#8220;The completion of this facility marks a
        significant step forward towards commercialising BrachySil&#8482; and I am delighted
        with the progress made by the team at Auriga Medical&#8482;. All key steps and
        facilities involved in the BrachySil&#8482; manufacturing process are now operating to
        the essential GMP requirements necessary for regulatory approval. We are
        now in
        a very good position to rapidly advance our clinical development and
        commercialisation programme for our exciting lead product.&#8221;</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">*</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>AEA
        Technology QSA GmbH is a subsidiary of AEA Technology plc (LSE: AAT.L), which
        announced on 13 September 2005 that it had reached a conditional agreement
        to
        sell a portfolio of non-core assets, of which QSA is one of nine companies,
        to
        private equity company Coller Capital.</em></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        Limited is currently in negotiations to acquire a US based drug delivery
        company
        with the potential to create a global drug delivery company specializing
        in
        nanotechnology, with revenues from existing products and generating long-term
        value through its diversified late-stage product portfolio. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="center"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>-ENDS-</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Released
        by:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div>
        <table cellpadding="0" cellspacing="0" width="100%">

            <tr>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
                  Limited</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Brian
                  Leedman</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Investor
                  Relations</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
                  Limited</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  + 61 8 9226 5099</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">brianl@psivida.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>US
                  Public Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Beverley
                  Jedynak</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">President</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Martin
                  E. Janis &amp; Company, Inc</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +1 (312) 9 1100 ext. 12</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">bjedynak@janispr.com</font></div>
              </td>
              <td align="left" valign="top" width="26%">
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>UK
                  &amp; Europe Public</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Relations</strong></font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Mark
                  Swallow / Helena Podd</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Citigate
                  Dewe Rogerson</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">Tel:
                  +44 (0)20 7638 9571</font></div>
                <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">mark.swallow@citigatedr.co.uk</font></div>
              </td>
            </tr>

        </table>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
        <div id="FTR">
          <div id="GLFTR" style="WIDTH: 100%" align="left">
          </div>
        </div>
        <div id="PN" style="PAGE-BREAK-AFTER: always">
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>NOTES
        TO EDITORS:</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>pSivida
        Limited</strong></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is a global nanotechnology company committed to the biomedical sector and
        the
        development of products in healthcare. The company&#8217;s focus is the development
        and commercialisation of a modified form of silicon (porosified or
        nano-structured silicon) known as BioSilicon&#8482;. As a new and exciting
        biocompatible material, BioSilicon&#8482; offers multiple potential applications
        across the high growth healthcare sector, including controlled release drug
        delivery, targeted cancer therapies (including brachytherapy and localized
        chemotherapy), tissue engineering and orthopedics. Potential diagnostics
        applications are being developed through its subsidiary AION Diagnostics
        Limited. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        owns the intellectual property rights to BioSilicon&#8482; for use in or on humans and
        animals. The IP portfolio consists of 26 patent families, 33 granted patents
        and
        over 80 patent applications. The core patent, which recognises BioSilicon&#8482; as a
        biomaterial was granted in the UK in 2000 and in the US in 2001. </font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">pSivida
        is listed on NASDAQ (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSDV</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">),
        the
        Australian Stock Exchange (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">)
        and in
        Germany on the Frankfurt Stock Exchange on the XETRA system (</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>German</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&#160;</font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>Symbol:
        PSI. Securities Code (WKN) 358705</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">).
        pSivida&#8217;s shares also trade in the United Kingdom on the OFEX International
        Market Service (IMS) under the ticker symbol </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><strong>PSD</strong></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.
        pSivida
        is a founding member of the NASDAQ Health Care Index and the Merrill Lynch
        Nanotechnology Index.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">The
        Company&#8217;s strategic partner and largest shareholder is the QinetiQ group, the
        largest science and technology company in Europe. QinetiQ is the former UK
        government Defence Evaluation Research Agency and was instrumental in
        discovering BioSilicon&#8482;. pSivida enjoys a strong relationship with QinetiQ
        having access to its cutting edge research and development facilities. For
        more
        information on QinetiQ visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.qinetiq.com</u></font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">.</font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">For
        more
        information visit </font><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><u>www.psivida.com</u></font></div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><br>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="justify"><font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"><em>This
          document contains forward-looking statements that involve risks and
          uncertainties. Although we believe that the expectations reflected in such
          forward-looking statements are reasonable at this time, we can give no
          assurance
          that such expectations will prove to be correct. Given these uncertainties,
          readers are cautioned not to place undue reliance on such forward-looking
          statements. Actual results could differ materially from those anticipated
          in
          these forward-looking statements due to many important factors including:
          our
          failure to develop applications for BioSiliconTM due to regulatory, scientific
          or other issues. Other reasons are contained in cautionary statements in
          the
          Registration Statement on Form 20-F filed with the U.S. Securities and
          Exchange
          Commission, including, without limitation, under Item 3.D, "Risk Factors"
          therein. We do not undertake to update any oral or written forward-looking
          statements that may be made by or on behalf of pSivida</em></font></div>
        <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
        <div id="PGBRK" style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt">
          <div id="FTR">
            <div id="GLFTR" style="WIDTH: 100%" align="left">
            </div>
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
          </div>
          <div style="WIDTH: 100%; TEXT-ALIGN: center">
            <hr style="COLOR: black" noshade size="2">
          </div>
        </div>
        <div id="HDR">
          <div id="GLHDR" style="WIDTH: 100%" align="right">
          </div>
        </div>
      </div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
      <div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; LINE-HEIGHT: 1; MARGIN-RIGHT: 0pt" align="left">&#160;</div>
    </div>
    <div>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>v025743_logo1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 v025743_logo1.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`3@$$`P$1``(1`0,1`?_$`,X```$#!`,!````````
M```````("0H#!`8'`0(%"P$``0,%`0$```````````````4&"`$"`P0'"0H0
M```%`P,"!`0#!`0*"P````$"`P0%$08'`!(((1,Q(A0)05$R%6$6"G%"(Q>!
MD5(TH6(S)+4F=K8W&?#1HK(E=4=7=[<Y$0`!`P($`P4%!0,%#`L!```!$0(#
M``0A$@4&,4$'46$B$PAQ@9$R%/"AL<$CT4(5X3,D-1;Q4F)R@I*BLC1T%S=3
M<[/#1*2T)74G"3C_V@`,`P$``A$#$0`_`)_&BBC111HHHT44:**-%%&BBO.<
M+"FM0B0"<-@B<1$U24ZT(6I@I3^G5['!"UQ*5;Y,CW9F-`QXDTU_RV]UKCOQ
MON-'#]K-;AY%\D)AR1G!8&PRW+<]Q_<SJBDV1N62:$<Q<`CZDI04(8YW)"B(
MBF4.H;46GRS,S.1L?:</=[>7!:8&Z.I.BZ)=MTC3XY-3U]Z!MM`,SCBA<X_*
MQK`"XEQ`1I'&DV1^*_>`YDMBSF5LY6A[>./G92+,L<87BT+TRRLR4,91N-SW
M1+R*Z$/(BF.Q9N@N0"G*-2AX:N:ZWMBF#T/+^3C[5]U-TZ7U4W2\7&K74>AZ
M:3A%$`Z9$PS/+G,X(K<AQX.I->-'?+O@U[I^`.)4ERGR-R]Q;R%L>7NVXH[)
MQ"'F[/1C$+A`\VT4;NG)(Y2*<0A7`"F/:<(FVG+6@ZVGRV]Q;E[1D=AV]_:3
MAAC[33?M/[3[/ZGV&@W%_-J6D:A;O>1)E5AC!\7@#1B411@G?4G,A"U`1'<H
M4H%$?QI0P_M-\=(I15YU(1R%V8<%JKJM4HT44:**-%%&BBC111HHHT44:**-
M%%&BBC111HHHT44:**-%%&BBC111HHHT44:**-%%4CF.4?*%0VCT\`W?"H_`
M-6$OSY6@(GOJ[#*3SKS!E$4E@;+NVB3H3B!6IUT2K&*;Z3[#'`]`\?#KI,EU
M6TM9Q9W,\#;YQS!A>`<G-!Q4"KXHI)6N<&G*!QKT"&.-1$Y1KT*4*4KXU$:5
M\-;KGOP?&YIS#!N"'_*JP`CYQ07N&$1!8!`!VB`$*(`8/J"O0=7QS9G92`4P
M*'@>8JU[22K2@H,)P``[HU$X!4$P&G3J4?$*#\]6RR($8[Q.*`X%/;5S1CCC
M6LLS9:M;"./YS(]Y+RJ4!`H"JY)!6_+71,NE#$,#=G&04&T>R3]XY6`"D(1,
M0J/F$H==;<$9FE#%:&\R36G>7L>GVS[J5CY`T+E:"2>X`8E:8:?9/]Q7W4)5
M[;V)(*Z>"'#=5PYCYK+]R,'T5GC)S%JL1%XRMF'<"W=6ZP<H@:IB)D`@@)%5
ME.H:4+BWT_3X7,N9C]>XK&&@.+N.!"A.(0@X\SRKB=U?=0NHUP;'289M$VSF
M(?.]?.D:J(UKF^'$.!)0\P`H(<XXE\">+W!RWCM,4VBW_-LIN_,N6+S5;2V3
M+M>+$JX<RESO@0502<G-_=VG8;T`*E,8*Z0+_78+,"34KJ*&W<@:V0M8A]HQ
M/<*Z?M;8NB;3B$.D1/EO'`F2=SB^5Q(Q60DN&9`$7NX84K6]+VM+&5B71D*\
M9IG!6;9]O/[HGYI^=`K9C$Q3-9^_="H83D6VHI&`B85.H<P$+YC!K8AN(9RT
MLD#XWG`MX)VK[^-."^N(=/L);R_?DACC<]Q>5R90J%?9]U,M^VAC3(7)7D7F
M3W2,W6V\MI3*3<MA<4[1DBB5:UL',#"S0N<K9PGZMDYO%H0@``@D(D56.)1`
MQ3:6;V"&V9Y$95PXGMY]J8<CSQ[:Y%T[L9MQ[CFZBZK$]AFC,=HQQ/Z=N,%`
M("&1PSD<4+1^[3\J(*`L<-U4R[J@-!'<(C\?'X:14`E7FE=C!=F/]ZM7FLM5
MHT45P-:=!I_175"X#CQH0GA5N9P"?13J(TV[`K6OA\M8#,]@_5;B>"8U4Y50
M57`1,4!#H(@'[0&E?#64YG-\)RGXT8+W5P4>M-^[H`TH`4_'I\]5:K0&O*O^
M%"@\!0<:%$=P%I^\-!#_``ZH^1D;#(\@,'.JMXHBU;B=;QWE+M^HM`$1'I4`
MZ>`!\=8YGR)EBRB0HGQQ^ZAHRA9.%7"9P.7<`[@J(5\*TZ5_IU?&_.">QQ'P
MJA3B.%=]9*I1HHJBH*@&`$Q^HO[P!M`:^->M34^&KVY>+N%6N+DRL'B[>ZNN
MY0!KU$`,4OF*!=U>@F^-`#5@&.)P^V%9'!&@#%QJXT5;7'6OCTIX?C\]'+OH
MJDH8P"%#B7YT(!J?B-?#5OBY)5P87<"E<I'`P#Y]X@/4=H%\?A350'<Z"QS/
MFJKJM6T:**-%%&BBC115(XT.3Q$1`P`'7KT_JUC>I.4)C[?RHPXXK2/<[8,M
MV><RN02LKFE;@<"S9GCXZ[(RVFB::(>G3>D=3!4V2(MNZ`FJH7<(=-0<]2WI
MQT+<DTO4&T?K-QN*3)&(8;RQM8`"4#GOO&-:&M)5RR@(,:=>B:K'&!:W,;!$
M[PEWB)#3@3X3R'OK3.`<K7;8&0D,27L]</8J5.5&*,YD&DRXB'JR0N&:9)=@
M\>M7#5V@&TQ=YMBHAMH`B&H[>F7K?O7I[U(;TAWY*V?2IIO)B6>*Z^F>4>P"
M>![HWM+5#LKG^)R8`)2IJ^DV\T+KBT.9@"M<<"1V$8'V8#A2E<N8FG<D2;*5
MB,C3MF"UCSL0CXP%RM5W"BW<(Z<]IPV.*J--HA6@D'4S^M/0C=W4W5V:UHFX
MI]*EB@#&Q1%(W.;F(<Y&ERN+D=XN`")BK?T_4K.R;]-*UQ60^(<2<`GNY<N-
M-@R=X7W$2<C%K7M<BJT8^>1RBA)B3*F==DY50!<A/6'VD5[0F`*B(`-->,.X
M>H_4_;NM7FWCK=Z\V=[-"2'_`#.AD=&XA0O$%,4KHEGI\,PS/B+2!F7,#X2.
MQ2O$8<>ZE48,Q9?.3K>+>*F6KO@VR$PNP19M9%X[,<T8=(S@5EEWFXR3@34$
MNWP'4T?3)TIZB]8]LMWUJ>Z[V'3(+XQMB:2'/,?EO<'JQP1'@!/?C@&UJ.HP
M:=(ZUFMR9W#CF'#$!$/=2FN0667&)K*3/'@![GFZ1<(=?^*1,Y4@[\BH41`I
MO3)@!@+XB8:4U+7U1];Y>A6P[6UT=Y?O"^C,5O(YI=D$;?'*40*#E1>)=P14
M1-(TW^)W#W2-6T85(!`5>6/+C\*2/C3#S_)K\CS(Z-TOU)U%>53N!I?4$3TK
M0[=,4"'M]1=Y*MW*RAC5,!$2)4"H`.H1=#>A>O=;=9_B75F[U1[KX?41W5KJ
M>EN:UC<0)K4&6Z)D<TLRLC:&-<'.`"FG%JFIV^DQ>58Q,(:$+'9BI."@@@#*
MH=B>(0<JXS!Q\FN95T6M@N54EH;A=AR2A9+(R(.%8^9Y#W[:RS5S;]@(NB!4
M^+;87;)K3*P$*26=AZ9/^$4QR^O^RM#T[8^WH=MZ6U[[2WA;&Q\AS/RAH:JX
M8E`24]E<5W-I5SNJ_9;7ZMT5C@^1"%N"""&D#$-&(<"F94X*KG<8Q0C(]E&,
M62#!BP:HL631HFB@V9LVJ8(-&S9!&B:*#=`A2$(4*$*``'0-*;S-F)&(6G*(
MX8@(H0&Q-```X``)5W4$:5Z$KU,;KYC>`=/^K5S6J<SOFH`/`<.-<BX1*%14
M``"M1H:@;:5J-/A75Y:1QJK`9/DQ2N172#;YJ[A$H4*8U1#Q^D!^>K'/#`IH
M<"TH[B:Z++D3V`/435$.AAZ%*(UZ!^&K'/*-+?D)0GLH:1GR'B:0_G?E0YLR
M;=V98[1F\F6)TDI>6?)F59QSA5$%R-FJ)3E]0Y33,43B?^&7=2M0'7G1ZE?6
M?>["W!<[$Z?1Q.UBT.6:XD:7L:\%',C1[5(&)*$8A%((IXZ=MQT\(N)6JTA>
M(``Y$\_A27R<ILW%4*Y-=+<Z9U-W96A8WT`B'G%/?VRJ&I6G0]1I0.NH<0>L
M+U&V3_XC-?2&P<]1G@&1RDX#PC#`_O*!B>VENXT728PV-F3ZE!@CNSMX4M#`
M/)5KDQS^6;H1;1-W)H'4;BT[GVV;(B%5E&I51,LV=D(.\Z1Q^D?*(]=3Y],_
MJ\L.K-ZS:.[VLL]VB(&-P!$=TXAY<UGB?E<QK2XYB&N&#%(--S5]O364!N(6
M'RP<<1@.WV=W$<>%*.N\[G\M39F'?,Z-$R7I00*(K`N#!R*)T.G^4[@EH'SU
M+W>DEW%MNY;9-+KPQNR@<2<I3NIN6S0Z7'Y?L*;4P?\`SB/E2SS7&3))8;[B
MZ^X??&TN2*!$(UX)?5&<@*`$!;:):_OTIUIKR4]/.K=?KSK9H\>ZSK$>V&33
M-E=-#*V,-$$Y:#FB"J_*A"XD8I3[U*TL6Z1X96OF12.?*G1VVQ`#E$1`HBF)
M=U1'=L#=0*5VA3QI37LG$&MC4<#BO<<:8.496M:F8`K5SWDJ`;=T,(@`T-01
M#Q^'PUE'B"BL?%!VUW$Y0`!KT'P$.H?UA75"X-*'G50"[A2;^79KS#C+R`''
MGWT;X+AR_CV<6URN37*%SEMZ1&'/`E9@+L\L+S8#<$O/W*4ZZS6Q`N6N?_-B
MDG7A=C1+M]F2+CR'94Q.9,*BI^T$?W+2<Y\6J<D1Y>DQ,%K7VI/!EEO?B=E"
M]_++@L,,B$TB$=ZD'R@`@!Q`V^E/#3FOW:=-;$6A!>G81R/;WU%OI%J'5@[Q
M#-W&<Z1Y3_FRD`X)\N/!<>%3-_4)=/,(U$"]"'\3!4*^7Y::;B&E'<:ER00`
M3P/"NHKUW"7J4O\`BF`_0?,.T:&H`?&E-`!)7DE58CSW</?46[WD?=2Y=<,^
M4D)B?!<U8L7:+_&-OW8L2Y;,9W'(*RTB^DVRXF>N7*9R-C)-R;"`7H-:Z<^F
M64-S!G<%/<4YG]E1>ZW]5]R]/]9MK'2&PF*5F=V=F<H$!`1[>WG3X?MYYNOG
MD3PPX^YNRFK&*9!R-8P3UTKPS!.,BUY$LS*LA68Q[<RB3-$R3(H;"B/F`1^.
MD*\9''<NCA/Z:D"N\;*UVXW+L_3]>NP!+<V[9"@0*0N`X@#OI:8*%$!'K0H`
M(^4W4!"H4Z=:_AK6:'G!V!6G.2$7E0*R8!434"E>H"'3]@A4-4<0PH[C5S07
M#,.%=2KI&`Q@,-"?54APIX^`"7K6GPU:9&CC5H<"J<J.^GV>_4>W2M=HUI7;
M]--WCJY0B\JIF&7-RJMJM7504&BB7E4-6O4M=H?B:FL,F4.!(>3W*GOHQ7E6
MI,VD2/C6ZO5!;QVJ2"*RPW6B^<0*:9'*/]_3C_\`.SI!2H`G40/XZY!URBFN
M.FNIN_H(B9`\DW8:;<`-)_6#@1D3YUP0%<*4M,\H73'3?S>8+[%Q^QIJB?=,
M65Y6C(1*]D@#9_&*E)8!)QI'(*L95J?<Z2F`*IZM1$X[-@"42@(;JC37B-NR
MY9I7432-8TR31@_SH7$Z8(Q"")$*^6UH!*>)#P(*<:Z.'P3VQ-O_`#3&DX\>
MS\\*4KRY]QK$_%R_L487:1:V4<\9HOBU;4M3%UJKD7EXR.GIADPD;TN?TC:2
M<1$+',G1UB$,CWW0DH0`)N4+]$ME:FZMFW`3(<I)'?S/VQJ-NY=^Z-M[4[71
MD=-K5U.&LC9XG-:7`9R`"0`,Q4@8`XTC6]0#\YW?MIM"Z)BE/``^X.Z`%!&@
M4_'7S+=3/^8VO=G\9OQ_YJ2I,Z2[_P!OB8XEKRT.QP5>7W_=3G7#C_@X/^U=
MR?\`>;Z]>O\`\_/^0S__`)J?_LK:F7NW^MV_X@_%U:+YMO2N+KL2,.H1))I"
MOG0BMW#)E6=/6B)5@(F!E-J:1!`PE`1`HCJ._P#^C=P;C>&V[&/.TMM;@.)<
MD9S/A(..`1/?PK<VNY\4<Q"9''%>&';6;<:&D.I>S\S4N)UE$K;52.>R&EP)
MRQ"+."$.#E66VH>E5*'F`H;ZT^&NL>D*VTMV\YW02;5FN(-+:C]-;")PYSW!
MV<L&;$("I5.."5K:Z8GVH?%@CD]W[%QI=+9JDS3!!N1-%N0H%102)VTTBA7H
M4@#L"M>M`"H]1J(UUZ,4T*N=%%(J]P7ENKP>XNWOR,1L8N1CVA)VI'A:9IP+
M<!^%S7%'P(JC+#&RP-_1@^[M.P??LV]*U#=L+3ZVX%N"B@GX4T-\[I&S=N3:
M^83.(BT9`4)S%.P\/93-.-/U(N();$.6<AY8PP\L6Y[1E+8@\<8WMV]VUU7!
ME"2GVTNX>J%6<V[#-;<A(`6")73M4JQ`%R4`#=0!5O[.R&0"-P(Y\?AQQKCV
MA^H_;.H:)<ZG>1/M[R$D-B4%SL.(P&"X$IA[EI,V/?U.=QFR(D7*7&RWF&)%
MY=-N]>69=K]W>EMQ"RH">371?Q*,;/+1[0=RR"1&ACB`@40KJ^?0@(_#\W>#
M^9IG:/ZIQ/J[(=6L'16$C_"\.S.RD@*1E["H0D'WU+&L6^K9R;8]JY"LN21F
M[6O*WXVX;=E&I@41?1,NV3>LW)#!U+5%0`$!Z@("&FGJ`DA@EB9R8X_Z)1/>
ME2YTN]MM4ABU*`@P2L#F^PX_'B*92N4QEKUN`\J!R'/<TN>5W`;OF0+)N#.*
M@(@<50;``!\:4IKYN-ZS1/ZJWL^YQ,ZT.J_K@$Y\AE'F`<U+<R<\U=E8IMDB
M^4/'^:N'V[*=\86GCV_;(;QD9'6Y(6K)0B31JK'(QZIFM6A"`<JJ*0*-Y!`Y
MA$QMP'*8.O77N+H^P^E'4[I5#HFCV>F7.W)=.B;%)$V(R,?Y0&+FM5LC79LQ
M7,'`J56N>W%UJEEJ)?<%Z9R4*HBX)W)PI,^-N(-PVW=D1<DQ>;-@>!ER2$<T
MA6:[AP\1:'5(U3>O%U6W:!=F>BP`0X&']FHD=(_0GNC:F\[?>&K:U#;FPN/,
MC9'"9'2!<?%YK!&O<UZ`N;SI5OMQM?'Y+<SPY0AY!$[UI<\](&AX>2D2H]\&
M$:]?G2!04`5]&W47V%6VJ=D3BG3Z1\?#7H]K^I7&D:#-J'E-G,$9<0Y_E9LH
M)XY7(J=APIK0Q-EFR9LJGVTCS'/+-Q?M\6]:)K%4BB3SE=H:1/.G=^F%)DY=
M$4].:+0`_5';]9?&NH(]*O7%<]4.I.F[#_L_%:?5S2M,HO?-RY(97@AGTL>/
M@3!_.G'>[?=:6/F&0%R+A_=Q]E)R]T3W)+A]N.*Q#<9,()Y<MS)DC/V\O*#>
MREI#;<W#MH]XS:*@2W)U-ZG,-72ABB8R6TR5``U>GH[86ANSY?[P`6N!=4.H
M]STUTZ#418/O+>5SFN<TIY9"(OA=\P7LQ"<36V/;6Y[1GN#8#E,R(6&7&LG`
M7[<%C3=H?F(+G!DM%-8U^RE`D0B8:J<HSD@,"?8H42#YC5Z5U*S?I\F1Q4$`
M_;V4M].M[VO4#;[-:AA,#P\M+"02"J<0!Q!I`GN&^^<QX/<C9G`,1@8F45+6
MM"W+@N"Y2W^6URLY"XFRL@G"DC@MB8!11M'IE.8_>*(F.!=@4UM6FEFZB\XX
ME4_/\ZYQU*ZZ6_3S<C-NBR=.][6N4.`^8D<"T\"*<^9\EK@1X5CRVN+'WV::
M+@1?-*V,BSZSOTJXVL>ZV<`I<"L:B<BBS02$,OZ0!)O$>V-*"GMMPZX;$#B2
ME=D_CES_`&<=N*:'R\MIYGEJ"N"HJ#EW4U3P#]]"1YO<F[(X[J\="8\0NJ'N
MF6<74;)@7$LR6MF'5EBHDBAM.)%RF\,0$Z=\HIAYJ#X:4K[3&V<>8N!<>`]R
MUQ;IQUZAW]N=N@QV)A)@<\N+@1@@P1H[>>-/FYSS%8?'O$=_9JR5(A#V3CBV
MY&YIYX&SO"V8)B)&K)(PAWY)^L)46Z8=3JG*'0!KI&9$996L'&NYZMJUMHNF
MS:M>E+:!A<Y>P5%2D?U/%VI9%%S&<7()3$8R'839R&0'">05X@HG$CT'B,.>
M%922Z/F!J**I0,.T51`!'3F;H&>W$C3X^S$^_CA\#43G^JM@U9Q@TY\FDAZ*
M'(\@.1<N1.!4*135ON[\O<3<X.06.<Z8@7DTX*0PW;L+-0<XT,VF;7NB+EI8
M9"`E`)N;K+I)G*H19(QDE4CE-4!':"II5@ZVC.9WB`7LYD]IQQKE?7'?.B;R
MURUU32@X^7:G.UX0M+B$4'WU,I]HFB?MK\/51`#@&+E2T'J`@%RW$8!&E1H`
MCIEWF-XX#CG-33Z2([IMH;78-^@8?]&DO^X7[XF%^%=\/<.619CO-V8XQ%$M
MR14;<#.W[3LETX3*HWCKBGS1\LHXER$$#*-6R1S(E$.X8AJ@"A:Z)-=1BX>?
MTSWG^[30ZC]<=N["G=IT;'7.J-`5C"$:$/S%#CV#GRIJFW?U/&7BS>^[N,6.
M92V"+$%RTM:_Y>,GTVU0`YTWDI&2D>J<E:]44P$`\2@.X%,[>B#5S#S$P"']
MM<E@]6#Q<,%QI<C("<2'J?8A8`OQ[JDO\)>:^'N=&&6F8,2+OF[-.24M^Z;5
MG>VG<=F7*V235<PTP@01*<ADU04;N"?P7"1@,0?$`;=]9/MG9'_-VU*79V\M
M(WWI(UC2#^GS;S!Y@CCQX%,>-+!WE]-O[0;?#M]*?Y3;\J4KU\-::?I(OV6G
M+F&7,F'95UK+5U4C=L3AN^LI=P?5T+6E>G0>NK71M>A<.!JBA4YI6/71'_<8
M.8:(.%6CIU&NDFSM!%NY6:KG2,*2R#9X0[-58J@`8`5*)!,`5TW=V:?/JFW;
MW3;:1\5Q-;2-C>QL;WQR%A#7L;,U\3GL)5HE:Z,GYFEJBMNVD\N1KY`'0!P)
M!5"%Q!3%#W8TTCE@ER/S1T@NAD1^YMM:01.^NNT8Z`9MDP5*=,S%>$9D1<AW
MT1J=0/`0$!`.H^&/7%VX=0U>WU*X9KUQ=Z-<NBDDO+>PAB:&S9AD%G'#F:\A
MKBYX*#`(N6ND6MQ:6L)CE8UEK<,X#.[EQ7$@X<S6T>)_#?CNPS=E7FNV35OG
M.&:Y%N[D)6Z7+>34Q0B2WHR,EK5LENL*AXI%Z];*'7<!10R9P(02I[MWLOT3
MZRZ9U7Z9Z7KD-S;C4/I(X[J)I#<EPP?J!'`.*+QQ![>5<5_X>Z5H.[+O<V22
M759\IC?(CLC%*!B8-'/D256DIWB4/S;=AD@`41N::`@@-`VDDG9>@#0:`(:^
M?;J0[_[#U_L.L7Q7BH=<R'[UKO%D]ES!;F9Y==`8!$0CAP`'#MIS3A^Y0;X;
M,HLH":9+KN3NF,%"IE`S<3*G,:A2IIE`1$:TIKUT]`UY9Z?T`FN+^6.*!FK7
M+RYS@`&B&W)/'D!]R4R]TM?+JP,849!^+J2GG.Y!R;FCU-M)3$W!6R1E'`[M
MJ,5F7I?1*"N^=,6_9!%3<XHD`*#L-2O4-0L]36^8.JO7H#;$LNH;?TQL09):
ML#GX",3EK9FY262`AJM+26\2#2WH#8K;3R96GZG$$'AQ)XCCRYTLCCT+^43E
M+@D7=ZJ`HK]N9L[TMB#MERD9`JBCATT1BFS9PJBH`@2BH"6@`)>O77H1Z7&7
MFJ07^Y+ZXUF1A:RWA9?VVFVYR,1_F,^B@B>22YS3YI.`P'.FYK4I+&Q1QL8.
M+D5>.'S=_92G]2[IMT:**9C]_D*^V+FD.O6Y<5AT$0_]0H'XA0=*NB_[>WV&
MN-]>@O32][0YA^!)I@/].7@G$68N1V<)[*F/;;R`^QCC>VIFQ276Q1F&$%,3
M%PNH]])(Q3TJL>N\,T2*0AUDU.W41(!3==+FX7NM@UL!+0XXH>X5'CTN:1IF
MI;AU">\ACE=#;L<PN"Y2YQ#B%[1QKROU%N"L=XCY88KN''UI0MF(Y3Q*XE;G
MC;=CVL5%O9Z#N-]%'D/0,B(M$%7,<=(JNQ,H*"6OB(B.;;T\UQ$Z*5V9K1@#
M[^?&CU1Z)9:=KUA>V,88;B*5SLH`"QEF/MQ)_#&I&_LBW%(W3[:'&]5V8ZIH
M-C>5M`LLNHLJHPA+VN)I'D.8PA_=FABID*'0I"``#TTTM78]E\X,RM87$.5?
ME[DYKVX)4FNC%U+==-]+FF\<_D8GO#G(ON_;6]^1/&22N"3?7YCY%)5^[2.Z
MF[>,(%5=N@(`&D8DYA*GZE1,G\1N?RJ"%2T'H/E]ZJ/1_=;EU6[ZA]-(LVJ2
M#S+JR#@/,()<Z6,O(:'.!.8!X^496@DK(?1->?$T07+@&C#$*#V`H%I&=FY#
MR)BF64&!?OX1=%4$W\"_3,#)P<A_/ZN-=)@F@H.P0%0A`'Y&U`#9/53JAT/U
MMT&B7=Q921S?K6\C0YCLA*QN8\.P7FQS7=A2G)/;V>JLQ;G('#$?`X>ZG+\'
M9]A\M`NTD6I(2ZV30JCB.%0ZB#TA1$!>QBPE*95N`4$Q1"I!'KKUV].GJFT'
MKE%_`=6B99;S@&8QM)\N7`E8U<YP+<I+FO((3`$$*PM1T1]DXSP!Z<""F'9C
MS6MRWD*)[+N0U0,)8*9`HU-T-]N<B(?CU#4C.H+FR;%U1S<<MG+VCQ!I!^'P
MI,L6.ENVAP5ZI\2E-+<;B%'-MA5W#23=B`"8PA48N0`>@C3PUX;>D,^9ZD=O
M->`6FXNN0Y6=R1]]=!U]C8M,\&!0C[JNO?5PJAE[V[\J2;=H"\[AV1@,LPIR
MIB90B,`Z!I.H`8`,*2*\+(+"80*80%,M`^.OH0T281:B`]R1$A??AW]IJ*/7
MC1SK736])+A],!,2$S!L:N**1Q0+S10*:#_3&YB]%>G)?!+]<"I3%OVKE*);
MG6%1#U<*X=V]-@T`QDS&55;NVJB@TIM3+^(@O;JMU>R1/T"``??\>?W5QOTM
MZ]*YNHZ$XK;,/FM)XX@!.2#PDX\^0IGW+BS[G;[J5U1+=7O-LX<J_P`E1(J`
M=<B5HLKF"%9*I=%`.W3MV+$VVA`#=3IUUNC)9Z*)(SEE`&/>4"\^ZN1Z[YO4
M#K6;>X)EB.HF$-[612$.C0Y<,"%4J"H45/#YE0$;;_!?DC#1S1-HQA.-]^0<
M>V3W[&L?%6,\9,VQ:CM$$&[<A0$/EIDQ/#KG."I4X_&I_;AA;#M6ZMVKY<=B
MY@]@9P^-0J_8&`!]R_$%>O\`J;E(W7^U^3'PU_K*']6G=KUO#]%%*GZB'%3_
M`'IJ#'IQC9_Q+C*?^!E/O!:E2.OU%=VR,%[>#F(8KJ)(WKF"P+>E03/M%>+(
M>6DU4%"TH=`[A@GN+4/`!#PT@Z#''->Y7A4'WBI-^H/4KG3^G%P+9V4RO#'8
M8D%5'OX4U/\`IL<`XPR3>W);)N0;+@+UF+"B+&M6T?S1%,IUA"%N127D)AVR
M92*2Z"$@[)%HI@H!!,5(!`!"NM_6[JY@>+<.+6(J#[=U<<]+>AZ9>R:EJ%S;
MQR/8&ACG-"MQ<2!QXA%[4%)"]^["6)L)\X$8W$]EP6/8N\<;6U>$_#6VT*QA
MEKE=OI!JYD6T6@4C6,.\2:$%0C<I$CF+NV@(C7<T.0R0/>\YI,N'Q3V4T_4M
MI&EZ-NVVN-.@9$ZXMW.E#,,Z%H5."I[,/A4L'VDA4#VS>()4C455Q4X326*`
MT34_,=Q[%`J(?0H8!ZAU`!#34O3ENWN>$`D*_&I>]*7-/3;1&+E)T]@4XHK$
MY4S>W_3F7Q=>??YLYLY,VMD"`N;*+J^\BVRRL6?BYRZ8J2F7$J_ARS)[C6!D
MH\*8B0JB4Q2)@-`J/17BUQT5J(H&MR@8'%5YX#W\N^N03^GLWN[!K^K7WU%O
M)=E[XWC`L)*-4`<`G;X0A[JWOL8J]O;&G%^/MK%\#@FPN15H7?:3:T+7QV$(
MRO8MJN%Q;7''3L=#&4='C"Q12JB+X`/O3`Q1J(@)HUS>R70DD)13V<"/M^56
M^H*PV/I^R'6MN+:+6\[!"V/YG`/;FX8H`'%2>1-8)^E^FGPW;RTMP72AXA6!
MQO/'8"H;L!+(NI>.(Z*E])5#,U]AA"E0`M?`*9-QG*]O86_MI']*$D@T[4F$
MG*V8$>_`_8U,`VAV]OPIM^'TUI\J>&FWE:F5/#4O,??535:*IB>A]NW]RH&^
M8UIM#IX_'0O*J+BG=3:7N3>X):O!G%"*C)E^=.0&35U+>P5B>..=[+W5<BHH
MM"2CF/9D5>)VY#.WZ1EC``&=*413'<81*IV-I'<SM,SA':`C.\\&M7%QQ&`&
M)Q'MIA[\WD-GZ039)/N.Y!9;P#%SI'>%B-"D@...'`&L9XP8!Y/Y$XVV=)\Q
M\D+,^0\VF_EI@]M,QCV45;<TH9]#V9=D&U>(QLI.PC5?L+NB$1.!:)"!C%WC
M%_U!^G;0NL39!I.HWNCZF`6A\<ADM9PB+);M,0).&'F*G,T\>G.N;KT_;\9W
M<V.2^F:I#06^6I4`9BX\$XI[N7K+\2,PVV]4<6C=,28*%(+MO,2EONS;0`"B
M<A45D3B6@#0QS#^(Z@//Z(.M^S[I[^GNL-EP!):YUFI4J/YQZH.!!Q7@*Z6W
M<%E)"QLX6<'FU5&'+G2/I1%=M+2+!^KO=MI!TW>KF5*H!WB*ZJ3Q45%2[5`,
MX(<=Q@\U:TZZ\_=>L=4TO6;ZRU=7ZO!<S1S8N<3*R0M?XOF)+@<>)XTZF>5/
M'%+`@>O(>WE^5;YQCAO+>2[0]=;$ZS:6@O).FBD<YGY!BAZM%4H/#F8M&QTE
M.Z(A4!&@_'4H>C70/KOU2V:^39-Y]-LHW,L;VONC&UTGELSD0*C@6EH+L"4Q
M[T[4-6TRS>!<G]=%&'+V^WE2E;$X?.8=X@^N*_Y`C9-0JCZ&MCU44D^[8B!&
MKF50>IN%42%#Z03#K^&I@=*/0A>[+U*'6]Q;FG;*@\R"VB=#F(.;*9_/>'`X
MJD8)XTU[K<3)5;;,2(\!P:.THF*^WG2WF$>E'ILVK<*-VB781`1$YBI$3$I"
MF5.8RB@@'B)A$1^.O0[3+"ST^WBM+5G@B"!Q.<D)S?VTUIG&5QD)(/97K:6*
MP4:**9D]_?\`_,?-'^TV+/\`[!@M*VB_[>WV&N/==_\`EI?>QOYTR]^F#_XZ
M<K/_`(GL7_?!YI8W1Q9[?R%<'])7]<:I_NL?^N:H?J>CD'D/Q?3J.\<.W8?:
M``(E`+P4ZG"M2E$`&@_AK)M48O\`:/SK:]5I`O-)[?I[K_N_VT]3[%"Z4=[7
M^&'3D_91;R.2W*RAP$I2I)7S<"BAPZ&%0A2$$>@=:::>Z;FWLS<75X<MI&'.
M>Y?E:"237>NA`S]-M+`Q6(_ZQI?Z'*;%3V?B8"-E'TDXF)%M$HO6\6[1C&Z[
MLP))N'$@Z*BCZ;NF`@F*`AN^.HBVOK$Z(ZENFVVKH][-/J]Q<QV\;G1N9$7R
MN:QGZA\)!<X8@\*[J[1;H1AS4Q4@#'ACRX5[F5L*6CDV*=&D&2;&X2(J#%W$
MU132?H.!2$R17#A,$Q>M`,'F34$0I\=+?73T^;$ZQZ+<SW-K#!NF.`NCO&-:
M"7!N#9"`,[!V%P^4=E&F:K<VSQ&_&(%".P+Q'8::HL62>VAD&V)%F8Z4A$7.
MU;&,BH<4541?I1DBW*4#B)VKY-<1$OATZ>&O$[I;K6M;-ZO:1+I4P;=QZM!$
M7-*YFOE#'`EJ`K&7QJN(=C70YK6.XLI))"J!#^'XD&GFKU();0N<0J*9[?EA
M`M!`"G/&.!\OP$0KKZ#>H1?<=/=5FC"2NTV1`.US%^*URBQ#V7^'!5^!II[C
M;_QNL/\`\R=?Z,D->'OH_P#_`.DMN+Q^HNO_`$5S70=Q?U7CV'\*=0RK8,9E
M7&N0L93145(F_P"SKAM%\FL!3!V9^*7C15[9A`#BW[_<`*A42^(>.OH`@<&3
M%QXC+^%<?U;3HM6TN?3;@!UO/$]C@>!S!!7SE>'N;9C@'R^O*:F%74<:SX7/
MN'9E`!4(K]P<0%P6S`J*H@4YE/3W,P9JIF$!H([JZZ'?QG4-)B<W%P3X]E>=
M6RM=?TTZ@7T%RYS+0-FA>O,(XQDCM*@CL7MI;/Z>W!J^8N>A<F3B!GL/@FRY
MV^WKI9(3)FO2X7!(.WU"K".PJO?=NG8>(U3&E/$$W7)?(L6PMP'9[L1WT\?3
M?HLVN;YN-R7(+V6["YSB,?-E)(<O!?"00!SY5,GYS`8.%W*H!/O*&",G[#>(
MB`VE)B-1J->HZ:5N$E;[_P`#4V]T@#;=X/WOI9%^!J$C[`O_`.E^(/\`8O*7
M^Y<AI[Z]_5T7L/\`JFH)>G'_`)E1_P"X3?BRI!_ZD(@FX$VJ(`:@9ZLL*@41
M*!C,;B`@&'P*!C=*_/3>VU_MY]_X5(;U(E.G3O\`KQ^#J1_^EY,48'F(-0`P
MSN*A`@C01*6+NCS?/:(A2M-9=R'^E+_@#\Z97I3&33]3:3B'-7X&D1?J0.O.
M^U:_^R5G?Z4G-;NW!FC(_P`'\S3)]507<M@.?TC_`,6U)R]I9\TB_;"XG2+U
M5%!E%8E>OG;IPIVD&C1K<%RN7CE=00$I4T6Z8F,(T``"M=-R^9YE\YCE\4A_
M&I4]*GQ-Z7:3<RD!L>G-)/8`U:C2<V_=MY5<[\UI\;>%SFZ[,QU.74M9=HM+
M!65C[_R^LEO:'F)RXVQ47,-:ZZ9%E?2-CE(1H7>HH<?%Q6>DQVT?G7+?TD5/
MM]NVHT;WZN[RWIN([-V(D=D7",2M7,78AQS#Y0#@"A5`0<0:Q?F+[+LAPRX1
M7/R5S+EIS>.<#W%9$.I:5N)&6M*#5N>>3:2*[^Z)-=29NUZ5NH)05.DB0I@#
M;4`U9#K4,EY'86T:1./'LXGL[JT=[]#AM+8=[NS7[^:[W$PQD9N`S2-8<<SB
M2A)XIW+C2J?TOI=N3>6'6O\`J5CS_LS3\O\`AIK#N7YF'N'XFG7Z4L+/5&]D
MK:F,?N?]/GIM\JF#^]7?5:MI/_)KD!C[BYAJ]\ZY0DSQEGV!#*R+LB(D,[F'
MRPBA%P$6@<2BYEI=\)$$2@(4$XF$:%UFMXG3SB%@5QI%W!K=GM[29M9OWY+6
MW9F/>>`'OIC/VR..F0N:&;9/W4^8L4J^EK@DE6O%#'$J<%X?'EDLG#A%C=4=
M''\K51N1$I8Q8/XBIS+.SB85$C`IWTS(8OI+091E1RXAW;Q7O3OQKC'3C1=0
MWIJ[NJNZ@7NDD_H$+L!!%B6OR@!I<00KG9BF"X$5)%!L@&X0)03`4#>8_@4*
M%IYNE`^6D,QL<W*1X:D%F)7OJT7(4AP*0NT"%WU$QMH5Z&/2H[CT#I76)\<!
MRMD5H&#4)Q)PR\>>'LJ\-E(:]A!Q1#3$=X%WWI=Q4QJ(7--%`XEJ!2_<G)S^
M0`'<(A7H`".OFFZDM<WJ)KK,I<PZQ?(U3F=_29``O\H[S75K1T;=,B>KH;D<
MP`6CCB5_9SX4KGA_FUC<EL*X\Q6S4O64B+IG%;ON8J9RV#9H+.6X&CWMQ(B9
MM-W.)``P1K'NG2"HK'2H)=>S/H>VUKF@]#&0:_')8WDFK3OCC<$+XW16Z%"I
M`*.(/%*YGN+5+>?5FV>F#ZDM:CW\`W%W'@OL'/BE.3L4Q],0%CBNH43E.J9(
MJ(G,!A`3`FF8Q"@/PH(A34Q3'RD0]GLY5IYB,`5^W#W5=`D0#[P#S!6@U-0*
M^/2NW5S6M:N4(M6HI4\:J:K11HHIF3W^*_\`+&S13J/YEQ90/Q_F#`Z4](D\
MN^8XA17(.NI`Z:WZA0@]W''W<:B5^UUS%SAP=O7+.:\8X:4S-CM"VK<A\YQJ
M`N&[BW;9<23M6W)TDNT1>K0HA,E.GW#ME6R@CM5,F``(O#7+:VN@P/.0\CCQ
MP]PJ(71W=>L[)U2^U30K%VH:4+=GGY2%8P.&(&!+L3@."<U2L$]Q#G7=7N.\
MA+?R,O9/Y3:15KQV.L=6%%29[BESI*RCA\JHNLBR:#(34S+/0\J2?;`FPH4K
MK%ID4&G1O<UV8]O<%I(ZH=1+_JON"`Z7:RL@8#''$0,V:0C%03@4"A>+:G4>
MVG@FX./G!GCKB"[V@L;HAK#+(WA&&*`F9SETR4C<3]@ZW4-WF?W8$524"AB&
M`?#7/]:DAU.>:SF8'P3-<'`]CN7WU/\`Z;:')MG96G:8\)/%"W-[2I(0]Y^Z
MDU9UQ%,XNN]X\:(/4[2DWZKV!EVIC>E8=TW?4C71R`'V]TU<"/9-X"40$!`P
M5UX'^I7H/N7H_O:?5]+MLFV)KCS;26(O6,YE8T.".#H\.>`RHX\!(C1-5CFC
M$4J.'/`>$\_<??[*]\_+/*H6L6W!=1RCDS8&))P[5N$B9$J7;,L`=P$3*$2$
M`[@AN-]0]=+(]:W6.;I__8=\D?U0A$1OLH^H$8!8UF7R_++D0%Y:7*U2I)-7
M'0=*9<.N),@<23\SDQQ5/R5*\GCYBZ;R!?4-*`U6):]MR+>3EY1=)447BD>M
MZE)@R<F*)72SAUM[G4=I"B(CI&]+G1#<O4OJ%8ZY-;O;MVQNXYYI7%S,8SYC
M6M`:<S\[6*%:,KBIY5;JU]#96/EQO\+\V':41>U!Q]U.KWL(EM"Y0`!V?EZ9
M!,OB(&^WNA*;K7IMK\=>W^_7"#9]^(6YI3:O9_H'!.'*N<V0D?=!Q*>*FD^-
MRI2YLL(!4()S2+S:!3`(A2*D!K3\`#7AEZ2\]OZDM`F>'-B%Q=8IP)L[D#[R
M*Z%KLL$^C`,QF"KW\*>.[04*=8HJ'3!,>X!C%$IS`42#M+M`=HA\M>_L0.0$
MXN("FN9M:4:T\"5]XX5\]'WPL-L\&^XOEXC5L5G!96BK>RS!F$"$;BXN=L+6
M?10)4/*G/Q[FH^(F-7QT_P#1KQAL6QRE6J5'?_*17G#ZBMM?PC?TMS;!S;:\
M8R5V4*KT+2BXA&AI.(!)YXT_3^FEPT-M<8<MYJ=MP*KE_)A82*54(7>K;N.V
M*L>0[=4/XGIEY:66,(`-!$E>M.C?W#<>?<!K#X`GN"8U(OTS;?=IFS)-4D86
MSW<OB)7$-S`<?;R3MIYCG:11MPTY5*`J(MS8"RA_#\HD3I:4G_%$X^:H;:?+
MKI+MG+<,!'@`KM^YF)M[4)7OP^E?A_DI^%0EO8'<(?\`,PPT4JZ0F/9F5`$"
MG*83?ZEO=O3QZB/2FG9K5S%+:-C9R&'^::@EZ<'.'4MID:YK1:2-"CF2VI8/
MO0\>[CY'^W[E6W+*BW<U>5B.XC*D!"1Z8K/YI6RW:SJ0BV"-0%=VXBG"QR$Z
M"<R>T!J.FSIDTEK<A["CB?;V?E4O.KVW#NCI_?6<<9?<L87L&(.9JI]CA4.W
MVR/<IF/;ER%DB;2LE/(]G9(@8^'N>UE9D;:D&DW;[A92&?LG2S%^1%=MZA=!
MRBHGN'=0.H:=FHZ9_$8VW:H$3VGF>=0GZ3]4;OIA?3Q75I+-!<`-?$`,X<S,
MCL4*DN[40<*Q_P!R[/>=^5.5+#Y/9PQJQQ#"99LM3^3-J`Y7.\/C>U)56-)+
MO#/6C5Z[%Y+.S['*J:!5RC5,NTM=7Z3#!9X!V8A`?O\`S!_*J]8-:W-N?4K?
M7]<M'6MI-&]MM&6A0P9224Q4J.)..'(FIC7M[6O(WQ[-.'[.M]44)B\.,5_V
MU#N$E!*8DO/$O2)CS$4`=R='CA/S!X!IH3N:[4B\_P#2%/C4U.GT$LW1[3X+
M8$SOTA,O:[RR/=C4'SBIG:\^!W*FS,HN[);/;NPU,35OW58%T=R'>"+N.?6Y
M<,4NIVG"D3))-G)S-EP*8H&I7QKI]7L/UUHV.WDRO_NCFO''[85`K;6N:ATN
MW<+_`%&W>Z[8]WF1%#X7%IP*\2T-.!7LP*TY5[@ONK\B/<5P/=4+9.!U\8\7
ML?3%IS.3[G,[_,ZSZ?7FB1]GL)*Z'$=&1T8W^Z+I&3:,BJ.%%1`3F$E:)6GZ
M=;6-P#>$.FQ(X]F!4)W\:Z]U+ZJZ[U`VQ)%I&GRVVTLS!<2.RERYAE;B7<9,
M@!85500.:N?TOSI!3)_*Y(BJ7=-8^/%0`IP,.PDV][@[0$1H(F\?"ND_7W,E
M>`S%/PQIW>E'+'8ZIYJYS*WCAABGWU,AZ4_#]O3Y^.FY4O5YU1.H0P'('42@
M&X#;@Z&\/#J.K8WB0*S[ZH4Q7E4:?W#4)SW"_<NP)[=C-]),L'8;BTLV<BDF
M9#I(2Q@;DD6C!VMN$AB#'F1CVM0'8[?J''J4FEJT=]+:/N4_4)1I'81C[.(^
M-<`WY!)U`W[9;"MY"[1;5GGWS<I^8.6)F8^%P<`I"'`)4C2!A(BV(>%M^$CF
MT-`6W'LHB#C&!2),(Z'C&J3*.8M$$2["-F[-`B:29?I`M.NDM[R_%N+R<>7P
M]E=]A@BM(6Q,:([>)N1C1V`(,/A62*.$DP*(B80,-`V%,?X5Z[0&G0-8S@%J
MI<!V_`TCOE9SEXT</X1*4S3D%G&S<JH5M;&/X!%6XLCWE(F)1O&VY:48"TBY
M7='4*1-58$6PF-03UUL06%U?/8VW``SC,78!K20KB<$08TW=Q;PT+:\#9=5F
M;YI_FXF'/+(X\&MC8KR21R"\45#3'SFPLP<BW,I?O(-.=XZ8-N>2>3]I<>H%
M^5MGO*4*^<JNFA\PSS,QPQ;9SY`P@NQ:#]Q<)&`-Q0,!M>7&\]H>G[TNZ_J&
M]MR75ONGJ_=WEW<VUD0'06LLD[Y(E(SM"L>WYB'J4&4@TM:5<[YZBP0G48Y=
M%VLJ%K`Y\D\:%,X:A8"1F.!3#'&GO^&B]JQN'(ZWH>.MBUX>$EI&+@[7M]HT
MAHN#B&@(@S;,V!!!0J9PJ)E%#*JKG,)SG,<PCKO?I.ZSW/4C8UUJV];^Q;N)
MNIS9;<2-:88C'%D:QKGEQ!)<@Y^^G5J.AQ:4]C-+:]UMD0NRD*5/(A>SCCS-
M+$:"D*!12``()CB%/GN&O[*ZE[;RF>(2XH>'LY4@.9D*(G/XU<ZSU2C111HH
MIF7W]Z_\L;-%`J8;FQ4!0^8_S#@.@?B.EK0,W\2;D`)RGX)C7%?4"X,Z8WA<
M_(/,B"]JN1/?PIE7],DW:N\U<K63YNU?-I#$UF-G3%ZD5PV=M%KGD"K)+H+`
M9!1)<H[3%.40.`"%-*VYIOJ0Q\7[IY<L`/NKB7I7:V75]5=F'\.=`QN4\WAP
M)*<E'$\ZE+VAPNXJV)>W\S;+XVX=MJ_C/3O4;JB;-A&\FT>+'WJ2;!0&HDCG
M8'\P'0*10!^-=-4W-SE\DN)CJ6MIM/;5A>C4[2QMX[\N\3FM"G'BO/G2H2$6
M+N$X"8QA"E3E\@%"E2_"IO$?QUJ/C;\X;F>*<I1KR6E6$\.RK>0CF\FV7;/V
M:+UNN``JS<%25;KEI_DU4UB*IF)T^)=)M]I5IK-H^SUF"*XLW\8W@.'OK*RX
M?;D/@/C'/A6NR84Q:"_K!QU9P.!,"@_^#M3;3UW=*IBGX_XHA^&N7,].W0UE
MQ]8-K:*+W.7YQ;M7,23F[SCB>VLXU34'',^5^;VK6PF$8C&HI-6+=)DU2Z)H
M-TT44$B?V$D42$(4/V`&NIZ?I%CI%M'9:7#%;V<:HR-N5HPY`5@N)W3>)SLS
MEXXK5TJV!9-5%1)-1)0AB"57SD.52I5$U"_O%,0?V:VS:1/C?#,,\3U4'GW&
MK&R%C@6E$[*Q".L.UHMVC(1]H6Y'OFYCF0=L(R/:NTC'*8AC).$D"G3$Q3B`
MTZB`B&F/I?3#I_HEZW7-'T2QM=9C)+71QM:Y7`@G,.XFMJ35+V4>4][G1'M*
MCX5EJGJQ2W)I%!8#E$I.X6@@'C4PT#J(Z?T0>N:3`D<.RDV0O+?`/$#6I[YP
M/B#)\DUF<D8EQU?TNR;`S8RMYVC;UR2+!EW16]"U>RS%VX1:%74,H!"&*4#C
M6GSVF2N9@PH*TKW2]+U-[9+^UCDE#44AI//M'?6:6=8]JV!`L+3LJV(.TK9C
M2K%8P5M1<="0S/U!A57]+&QK=LU;BJL<3&$I/,8:CK&)'N.=X1XK/;6T-G`+
M.V8UML.S#[J]67@HV?C'L+-1C&4AI-HO'2L5)((OF4G'.4S)+LGK5P0[=PT7
M(H(*$.4Q3%Z"`ZKG*KSK,^"V?$Z&1HDC>S*0>&)[ZU19W&W`U@33.YK&PMBR
MRKECFZK5C<-KV+;,%--FS@ADG#="4BHYL\1373``.!3%*<!H(>.J>=(XHX8>
MZM"TT/1;&9ES;6\;)VA%#0OX5NI1L4Y#$H'F^H!'H:@4K^`ZQ$R"0.'"E09,
M0X*UW&DMR'![B+)W\.3G_&K"K^^S.RO%;E=V'!J/EG0*`N+]9,6IF2\@#CSB
ML=(5!-UW5ZZW'7MWD\L/=D[.5()VMMIUS]:ZRA-X,0_*%7VIP[JV;?&!L.9+
M7BW.0L28ROIS",31D,YNZS(&>4BXXQRG48,/N+%P+)FH8H&[25"=/#6%DDC`
MN8YJW;C2-(OG`WUO'(&CPJ`4]BUFEMVC!69!1%J6A`0]M6O"-O21,%",FL9$
MQK7>=0&K1@S(BV:IE.H)@*F3;N$=8W.>Z7,>%9[2V@L(([>T:(X68!H1`.P?
M?6B,H<+^+&:+D_-^4^/.)K[NHW9%:Y+BM"*=R[@42E`@O7R:2+E[LV!3NB<.
MFMIEQ+'C&]P/=2/?[5VUJMZ;W4K"">X*#.YK24'#B*V0E@W$2-A'Q<CBG&Z.
M.#J(J&L,MFP!K/54:K).VJZMN"P"*571=($.4YDS'*<H#6H:Q/FF?,)G.*@4
MILTG2([7^'L@C_AY1690F!48<T(!Q6N;%P;B#%SE_(8VQ7CVP9&4:I,Y-Y9M
MHP%LN)!LFH"Y&SI:(9M5%T$ER@8"'$Q=W4-4=(\\#C]OC6.WTK3;%SS801Q9
MO[T`+]U;3_B^GIL_B[/HJ6M?[-=VRM.E:TUC3!*4T9F3]W^2M(<A,I(X.P=E
M[,"[%U*)XQL"X[U5CVH%]4\;P$:X?'21`U0[IB)#2O3IK,UBY6A%)-)6O:F[
M2M(O-5B:IAMC(1_BM<Y/NI'O&!EQ"R]E*;]P##>3;9EKOS9AFRK0R*V;W7#+
M(-R6Z#.5:KS$4HN23MN?C2@+5VF8Q$E03(<25+N':<9HH3;EIQ*\.X?LIK[:
MCV[J6H?VZTN9A?<6[62D'#,W$*%0$*?:M97R']T'@YQJC':^1,^V7(SC1%44
MK/L"3:WQ=SQ=N']W;Q<(NY0;K@?RU<*H@4WB(:QV]A<W7@#2AP)Q0+WBK]Q]
M3-D;:C>=2OX/J(P7B(.:9'AN*-:JDDX``\::?5]Q3W$?<:D7%H>WA@=_@#$S
MDQV$MR;S0U(91NS<J=H7<"0K9Q%LW`MA,=,C%.1>=.AR&`1#=%G;V)'U!#TX
M`'\\1W'B:YM_Q!Z@]0'_`$O3RP^DTEQ0W5RW+AAFRL`<I(*M)(&"4NOAY[1F
M)^/SU[F'*%ZW'R!Y;7`BH:X<_7XM]XD+>E'(BJ^''T3-).6T$*9C@1-RLFJ[
M*4@"04JB72#N]UYK^D3:/I\[K&.5I!DC^=H(0D8\4YJHI];%Z<Z1MJ]_CFJE
MVI;A)\4LQ)3',&M:<&M:24``'=@*5PYX9V%)NW3^1NV]GSU\IW7CEX]8JN7:
MPFJ8[AP=F=13>%0I4"A\`#4$+GT&]-]9OI]5UK5M3O\`497%Q?([Q-<2JKG4
MIP!/`)V5W2/=5[:O_1:&QG]T'P_#+A7+3A=CQJX1=(W->/<27;.?*^:(]TS0
MP&335].T3$4^@`(=*@&E#1?0ITYV]?17>EZGJ<,L3P]&N(S(X.0H_M'XU@N-
MQ74_S,0_XV'X4L)HB"#=)$`Z)D`@"-:FV@`;AK\34KJ;=E"VVLXK5I<6Q1M8
MKN)R@-4\>*+3<E>^20O>F8GE5QK:JRC111HHI-'+GBUCOF7@RYL`94>W%'V5
M=CZ`>R;FU7S6-G"+6],-)M@#-Z[92"*%7K(FX>T(B6H!2NMFTNGVDWG1_,`?
MOIO[GVSIF[=(?HFKM+K&1S20"A5I48BDR<'O:TX\\`+HOJ[\*S^29.5R)"QM
MOS9+ZN".G&9&D3(*R+15DBRAHL[=V554Q1,)CEV=-M>NLT][-=CQ<!]NRF_L
MOIMM?8#I/X)&]HF/BS.<[L[2>P4Y@4!`I0-01```1#P$0#6A702BX<*[:*I1
MHHHT44:**-%%&BBC111HHHT44:**-%%&BBC111HHHT44:**-%%&BBC116K<N
MACC^6N0PRL,:&.QLVXPOXTQWOMA+.-#/OS`>0[`"OZ0D/WJ]L!4I]`":FKHO
M,S-\M>(3^2M/4/H_X;=?6Y?H/)=Y^;Y?+0YLW/*BJG*H3$MQT]AF2O"8E;.]
MP?-ULV:Y?+N#VE%8.S?,FCFZBRAU&"-R%PVF*S1$@[4#+MU5`1`M3J!0PN,O
MU#R4>R->1.5?O=^2U"R31_3Q)>2R6^K:DR$R',R&.[,8/^"66A&7L1Q;V&G&
M.%-H_IS+1O*)9X[RE:F4LB&=(%BY;DE&9%BD"R95`H=@UR38%B6*110_T@=-
M2G3;K$/[09'9/,\G*5RIE3O3"NC[*MO3U:S1,T>XMKG4O/;Y;KD2";S%\.02
MQQN5>P>VI0T)^7OLL7^7/M7Y>]$W^R?9O3?:/M_:+Z3[7Z+_`#3T?9IV^UY-
MM*:0W>9G.9?,YU).+R?('DI].F&7@GNKU`[%/+LVU'Z?"NX:^'[V[Q^-=8C\
MN/RUF:N;P_,GW5P?TWEW[?'RUKX_#PU8_P`ORSG_`)M,:R#S4**E5AI4M?'K
MM\?EU_#PU<<JA?FY5BKMJH1,.%%&JT4:**-%%=#[*%WTIN+MK_:KY?Z:ZHY$
M\7"C#G7!.W0VSPKUI7Q_IU6KW9U&;C7<*4"GA0*?L^&BK"JX\:YT44:**-%%
I&BBC111HHHT44:**-%%&BBC111HHHT44:**-%%&BBC111HHHT45__]D_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
